Loading...
•
Dec 31, 2024
Tarsus Q4 2024 Earnings Report
Reported strong fourth quarter and full-year 2024 financial results, with XDEMVY net product sales reaching $66.4 million for the quarter and $180.1 million for the year.
Key Takeaways
Tarsus Pharmaceuticals reported positive Q4 2024 financial results, highlighted by net product sales of XDEMVY reaching $66.4 million. The company continued to advance its pipeline, including TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention. Broad reimbursement coverage for XDEMVY was established, and a direct-to-consumer campaign was launched.
Generated $66.4 million in XDEMVY net product sales during the fourth quarter of 2024.
Dispensed more than 58,500 bottles of XDEMVY to patients in the fourth quarter of 2024.
Expanded sales force contributed to increased ECP utilization and prescription volumes.
Broad commercial, Medicare and Medicaid reimbursement of XDEMVY now extends to more than 90% of covered lives.
Tarsus
Tarsus
Forward Guidance
Tarsus is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027. In Japan, the Company expects to share results from a DB prevalence study in the first half of 2025, and meet with Japanese regulatory authorities to help determine a regulatory path forward. The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application (NDA) submitted by Tarsus’ partner, Grand Pharmaceutical Group Ltd., for TP-03 for DB.
Positive Outlook
- Potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.
- Initiated market development work, including Key Opinion Leader engagement, disease education and scientific presentations at major conferences.
- In Japan, the Company expects to share results from a DB prevalence study in the first half of 2025.
- The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application (NDA) submitted by Tarsus’ partner, Grand Pharmaceutical Group Ltd., for TP-03 for DB.
- Planning to advance TP-05 for the potential prevention of Lyme disease.